🇺🇸 FDA
Pipeline program

DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

Phase 3 small_molecule active

Quick answer

DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN for Favorable-intermediate-risk Acute Myeloid Leukemia is a Phase 3 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
Favorable-intermediate-risk Acute Myeloid Leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials